Clinical ddPCR Diagnostic Test System Gets FDA Clearance
By LabMedica International staff writers Posted on 07 Mar 2019 |
Image: The QXDx BCR-ABL %IS kit and the QXDx AutoDG ddPCR system (Photo courtesy of Bio-Rad Laboratories).
A test designed for monitoring treatment response in chronic myeloid leukemia and is also the first-ever digital polymerase chain reaction (PCR) product to receive US official government approval.
The test uses a clinical instrument, called the QXDx AutoDG Droplet Digital ddPCR System. It is designed to give users the flexibility to run US Food and Drug Administration (FDA, Silver Springs, MD, USA) -cleared in vitro diagnostic medical device (IVD) tests, as well as laboratory developed tests, and uses a simple, user-friendly workflow that is also scalable.
The QXDx BCR-ABL %IS Kit was CE marked in late 2017. The test uses Bio-Rad's clinical instrument, called the QXDx AutoDG ddPCR System. It quantifies BCR-ABL fusions, specifically p210 transcripts, and can detect the residual levels seen in patients on tyrosine kinase inhibitor therapy. Measuring residual levels of BCR-ABL in chronic myeloid leukemia (CML) patients treated with the first-line tyrosine kinase inhibitor (TKI) imatinib, for example, can help physicians decide whether it might be necessary to start a second-line TKI, such as dasatinib, nilotinib, or bosutinib.
Digital PCR-based methods can offer lower levels of resolution than standard quantitative reverse transcription PCR (RT-qPCR). Bio-Rad's new test can detect molecular response down to MR 4.7 (LOD), or 0.002% on an International Scale, according to the firm's website, with levels of BCR-ABL between 0.01% and 0.001% defining a so-called deep molecular response that predicts better long-term outcomes.
Bio-Rad introduced ddPCR as a research tool in 2012, and it was quickly adopted for liquid biopsy and rare mutation detection in cancer research, the firm noted in a statement. To date, there are more than 3,400 publications citing the ddPCR technology, including more than 900 publications focused on liquid biopsy.
Related Links:
US Food and Drug Administration
The test uses a clinical instrument, called the QXDx AutoDG Droplet Digital ddPCR System. It is designed to give users the flexibility to run US Food and Drug Administration (FDA, Silver Springs, MD, USA) -cleared in vitro diagnostic medical device (IVD) tests, as well as laboratory developed tests, and uses a simple, user-friendly workflow that is also scalable.
The QXDx BCR-ABL %IS Kit was CE marked in late 2017. The test uses Bio-Rad's clinical instrument, called the QXDx AutoDG ddPCR System. It quantifies BCR-ABL fusions, specifically p210 transcripts, and can detect the residual levels seen in patients on tyrosine kinase inhibitor therapy. Measuring residual levels of BCR-ABL in chronic myeloid leukemia (CML) patients treated with the first-line tyrosine kinase inhibitor (TKI) imatinib, for example, can help physicians decide whether it might be necessary to start a second-line TKI, such as dasatinib, nilotinib, or bosutinib.
Digital PCR-based methods can offer lower levels of resolution than standard quantitative reverse transcription PCR (RT-qPCR). Bio-Rad's new test can detect molecular response down to MR 4.7 (LOD), or 0.002% on an International Scale, according to the firm's website, with levels of BCR-ABL between 0.01% and 0.001% defining a so-called deep molecular response that predicts better long-term outcomes.
Bio-Rad introduced ddPCR as a research tool in 2012, and it was quickly adopted for liquid biopsy and rare mutation detection in cancer research, the firm noted in a statement. To date, there are more than 3,400 publications citing the ddPCR technology, including more than 900 publications focused on liquid biopsy.
Related Links:
US Food and Drug Administration
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data